The Committee For Medicinal Products For Human Use Of The European Medicines Agency Granted A Positive Opinion For The Use Of Gilead Sciences' Veklury (Remdesivir) For Covid-19 With Mild To Severe Hepatic Impairment
Portfolio Pulse from Benzinga Newsdesk
The Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for the use of Gilead Sciences' Veklury (Remdesivir) for Covid-19 with mild to severe hepatic impairment. The European Commission will review the recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that can be used across all stages of liver disease.
September 19, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences' Veklury has received a positive opinion from the European Medicines Agency for use in Covid-19 patients with liver disease. If the European Commission adopts the recommendation, it could boost Gilead's revenues.
The positive opinion from the European Medicines Agency for Gilead's Veklury is a significant step towards the drug's wider use in Europe. If the European Commission adopts the recommendation, Veklury will become the first and only authorized antiviral COVID-19 treatment that can be used across all stages of liver disease. This could lead to increased sales of the drug, thereby boosting Gilead's revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100